Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;13(6):1158-1160.
doi: 10.1177/1932296819855425. Epub 2019 Jun 13.

New Design of a Percutaneous Port System for Continuous Intraperitoneal Insulin Infusion

Cosima Rieger  1 , Klaus Kurz  1 , Wiebke Mueller-Hoffmann  1 , Bernhard Gehr  2 , Andreas Liebl  2
Affiliations

New Design of a Percutaneous Port System for Continuous Intraperitoneal Insulin Infusion

Cosima Rieger et al. J Diabetes Sci Technol. 2019 Nov.

Abstract

Insulin-dependent diabetes mellitus is treated with intensive insulin therapy using multiple daily injections or continuous subcutaneous insulin infusion with insulin pumps. For people with diabetes who cannot achieve acceptable glycemic control despite the use of intensive insulin therapy and continuous glucose measurement, there exists the possibility of continuous intraperitoneal insulin delivery via an implantable pump or a percutaneous port system that is connected to an external insulin pump. In this article, the current second generation of the Accu-Chek® DiaPort system for continuous intraperitoneal insulin delivery with its improvements over the former generation is presented and discussed.

Keywords: CIPII; DiaPort; continuous intraperitoneal insulin infusion; design; implantation; percutaneous port system.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CR, KK, and WMH are full-time employees of Roche Diabetes Care GmbH. BG and AL declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. BG and AL received from the following companies fees or financial support for the participation in advisory boards, general advice, untied research support, or other medical-scientific services: AstraZeneca, Bayer, Becton Dickinson, Boehringer Ingelheim, Bristol-Myers Squibb, DexCom, Lilly, Medtronic, MSD, Novo Nordisk, Roche, Sanofi.

Figures

Figure 1.
Figure 1.
(A) DiaPort first generation. (B) DiaPort second generation. (C) Components of the DiaPort second generation.
See this image and copyright information in PMC

References

    1. Garcia-Verdugo R, Erbach M, Schnell O. A new optimized percutaneous access system for CIPII. J Diabetes Sci Technol. 2017;11:814-821. - PMC - PubMed
    1. Logtenberg SJ, Kleefstra N, Houweling ST, et al. Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial. Diabetes Care. 2009;32:1372-1377. - PMC - PubMed
    1. Liebl A, Hoogma R, Renard E, et al. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion. Diabetes Obes Metab. 2009;11:1001-1008. - PubMed
    1. Selam JL, Giraud P, Mirouze J, et al. Continuous peritoneal insulin infusion with portable pumps: factors affecting the operating life of the chronic catheter. Diabetes Care. 1985;8:34-38. - PubMed
    1. Renard E, Baldet P, Picot MC, et al. Catheter complications associated with implantable systems for peritoneal insulin delivery. An analysis of frequency, predisposing factors, and obstructing materials. Diabetes Care. 1995;18:300-306. - PubMed

Publication types

MeSH terms